Product Images Spritam

The given text describes a formula to calculate the estimated glomerular filtration rate (eGFR) for a patient. It involves multiplying the quantity of 140 minus the patient's age in years, with the weight of the patient in kilograms. This result is then multiplied by 0.85 for female patients. The next step involves multiplying the answer obtained in the first step with the patient's serum creatinine level in mg/dL. The value of 72 is also used in this calculation.*

This appears to be a table with three columns containing abbreviations and units of measurement. The first column has the heading "CLer (mL/min)", the second column has the heading "CLer (mU/min/1.73m?)", and the third column has the heading "BSA subject (m?)". Without more context, it is difficult to determine the purpose or meaning of these measurements.*

This appears to be a graph showing the percentage of patients at different levels of medication dosage for Placebo and Levetiracetam. However, without a visual representation of the graph or further context, it is difficult to provide a more specific description.*

This appears to be a table showing percentages of three different treatments: Placcbo, Levetiracetam at 1000mg/day, and Levetiracetam at 2000mg/day. However, without additional context, it is not clear what these percentages represent or what they relate to.*

This text likely describes the effectiveness of two different treatments, Placebo and Levetiracetam, with a sample size of 104 and 180 respectively. The numbers 39.4% and 14.4% may relate to the reduction in symptoms or improvement in the condition for each treatment. However, without more context, it is difficult to determine the exact meaning of these percentages.*

This text is presenting data about two different groups (placebo and levetiracetam) and their respective percentages, but lacks information on what the percentages represent. Therefore, it is not possible to provide a useful description without additional context or data.*

This appears to be a table showing the percentage of patients and the percentage of their response to the drug Levetiracetam as compared to a placebo. However, the values seem to be incomplete and illegible making it difficult to provide an accurate description.*

This text contains information related to a medication called "Spritam" (levetiracetam), which is in tablet form and available in 500mg strength. It comes with a modification guide and dosage recommendation instructions. The medication is intended for oral suspension and each cart contains 10 tablets. It also contains a unique identifier code "DG 348512580".*

This appears to be a package insert for a medication called Spritam (levetiracetam), containing various instructions, dosages, and storage recommendations for use. The text also includes a NDC number and a product code (RL-CTO00354), but it is not clear what they refer to without additional context.*

This looks like a product label or package insert for a medication called "Spritant" (levetiracetam) that comes in both tablets and a suspension for oral use. The label includes information like dosage, the medication's active ingredient, and instructions for use and storage.*